According to GlobalData’s medical device pipeline database, 221 Tumour Detection devices are in various stages of development globally. GlobalData’s report Tumour Detection provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 175 are in active development, while the remaining 51 are in an inactive stage of development. There are 66 products in the early stages of development, and the remaining 109 are in the late stages of development.

Diagnostic imaging devices are used for the visualization of structural and functional patterns of organs or tissues. Computed Tomography (CT) Systems, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems, X-ray Systems, Bone Densitometers, Angio Suites, Contrast Media Injectors, Accessories, Contrast Agents, Radiopharmaceuticals and C-arms are covered under this market. Tumor detection node includes the radiopharmaceutical agents that improve the visualization of tumors in medical images. It helps doctors see tumors that are too small to be seen on regular medical images, to determine the size and location of tumors, to assess the spread of tumors and helps in treatment planning.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Tumour Detection pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Tumour Detection devices. Overall, most of these Tumour Detection pipeline devices are being developed by private entities.

Key players involved in the active development of Tumour Detection include Telix Pharmaceuticals, Clarity Pharmaceuticals, Advanced Accelerator Applications, On Target Laboratories, Pars Isotope, Nuclidium, Akrotome Imaging, Starget Pharma, Suzhou SmartNuclide Biopharmaceutical and Starpharma.

For a complete picture of the developmental pipeline for Tumour Detection devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.